- Home
- MYFW vs CHRS Comparison
MYFW vs CHRS Comparison
Compare MYFW & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYFW
- CHRS
- Stock Information
- Founded
- MYFW 2002
- CHRS 2010
- Country
- MYFW United States
- CHRS United States
- Employees
- MYFW N/A
- CHRS N/A
- Industry
- MYFW Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MYFW Finance
- CHRS Health Care
- Exchange
- MYFW Nasdaq
- CHRS Nasdaq
- Market Cap
- MYFW 201.1M
- CHRS 84.2M
- IPO Year
- MYFW 2018
- CHRS 2014
- Fundamental
- Price
- MYFW $23.40
- CHRS $0.82
- Analyst Decision
- MYFW Buy
- CHRS Buy
- Analyst Count
- MYFW 2
- CHRS 3
- Target Price
- MYFW $24.25
- CHRS $4.68
- AVG Volume (30 Days)
- MYFW 53.0K
- CHRS 1.3M
- Earning Date
- MYFW 07-22-2025
- CHRS 08-07-2025
- Dividend Yield
- MYFW N/A
- CHRS N/A
- EPS Growth
- MYFW 154.12
- CHRS N/A
- EPS
- MYFW 1.04
- CHRS N/A
- Revenue
- MYFW $91,514,000.00
- CHRS $272,251,000.00
- Revenue This Year
- MYFW $17.24
- CHRS N/A
- Revenue Next Year
- MYFW $10.85
- CHRS $106.56
- P/E Ratio
- MYFW $22.48
- CHRS $1.90
- Revenue Growth
- MYFW 13.99
- CHRS 19.87
- 52 Week Low
- MYFW $15.54
- CHRS $0.66
- 52 Week High
- MYFW $23.85
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- MYFW 71.35
- CHRS 53.65
- Support Level
- MYFW $22.33
- CHRS $0.72
- Resistance Level
- MYFW $23.85
- CHRS $0.77
- Average True Range (ATR)
- MYFW 0.66
- CHRS 0.04
- MACD
- MYFW 0.21
- CHRS 0.01
- Stochastic Oscillator
- MYFW 90.45
- CHRS 91.74
About MYFW First Western Financial Inc.
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.